488 related articles for article (PubMed ID: 33918661)
1. Circulating Biomarkers of Response and Toxicity of Immunotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Review.
Indini A; Rijavec E; Grossi F
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918661
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.
Brozos-Vázquez EM; Díaz-Peña R; García-González J; León-Mateos L; Mondelo-Macía P; Peña-Chilet M; López-López R
Cancer Immunol Immunother; 2021 May; 70(5):1177-1188. PubMed ID: 33113004
[TBL] [Abstract][Full Text] [Related]
4. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
5. Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy.
Honrubia-Peris B; Garde-Noguera J; García-Sánchez J; Piera-Molons N; Llombart-Cussac A; Fernández-Murga ML
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503087
[TBL] [Abstract][Full Text] [Related]
6. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
Kloten V; Lampignano R; Krahn T; Schlange T
Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
[TBL] [Abstract][Full Text] [Related]
10. Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Zhu C; Zhuang W; Chen L; Yang W; Ou WB
Transl Lung Cancer Res; 2020 Feb; 9(1):111-138. PubMed ID: 32206559
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
12. Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy.
Papadaki MA; Sotiriou AI; Vasilopoulou C; Filika M; Aggouraki D; Tsoulfas PG; Apostolopoulou CA; Rounis K; Mavroudis D; Agelaki S
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545559
[TBL] [Abstract][Full Text] [Related]
13. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab.
Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A
Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of PD-L1 Status in Circulating Tumor Cells for Cancer Management during Immunotherapy.
Strati A; Economopoulou P; Lianidou E; Psyrri A
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371863
[TBL] [Abstract][Full Text] [Related]
16. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
Yao L; Jia G; Lu L; Bao Y; Ma W
Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Augustus E; Zwaenepoel K; Siozopoulou V; Raskin J; Jordaens S; Baggerman G; Sorber L; Roeyen G; Peeters M; Pauwels P
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33918147
[TBL] [Abstract][Full Text] [Related]
18. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma.
Ao H; Xin Z; Jian Z
Biomark Res; 2021 Dec; 9(1):91. PubMed ID: 34930486
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
